SUMMARY
Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs. Here we have established an HCC risk gene signature applicable to all major HCC etiologies: hepatitis B/C, alcohol, and non-alcoholic steatohepatitis. A transcriptome meta-analysis of >500 human cirrhotics revealed global regulatory gene modules driving HCC risk and lysophosphatidic acid pathway as a central chemoprevention target. Pharmacological inhibition of the pathway in vivo reduced tumors and reversed the gene signature, which was verified in organotypic ex vivo culture of patient-derived fibrotic liver tissues. These results demonstrate the utility of clinical organ transcriptome to enable a strategy, reverse-engineering precision cancer prevention.
INTRODUCTION
Prevention of disease progression has drastically improved patient mortality in several chronic diseases such as cerebro-and cardiovascular diseases, although cancer prevention has been a challenging task as evidenced by its almost unchanged mortality over the past several decades (Vogelstein et al., 2013) . The major bottleneck remains the elusive mechanisms of carcinogenesis, and the difficulty in clinically verifying animal model-based findings due to the requirement for long-term monitoring of large number of cancer-free, asymptomatic individuals. In addition, the scarcity of cancer risk biomarkers hampers identification of high-risk populations that could be used to design clinical trials with practically feasible sample size and follow-up time . To overcome the obstacles for discovery of clinically relevant cancer chemoprevention targets and therapies, we have employed a "reverse engineering" approach, where cancer initiation-driving targets are first defined based on long-term clinical follow-up in multiple patient cohorts, and subsequently validated by experimental systems.
Liver cirrhosis is the terminal stage of chronic inflammatory and fibrotic liver diseases, and a distinct risk factor for developing hepatocellular carcinoma (HCC), the major histological type of liver cancer and the second leading cause of cancer mortality worldwide . Established cirrhosis is a strongly precancerous state with annual HCC incidence up to 8%, and complete removal of HCC tumors does not prevent subsequent, repeated de novo HCC development from remnant cirrhotic livers (70% recurrence rate within 5 years of surgical resection), resulting in incurable advanced-stage diseases and a persistently dismal prognosis (5-year survival rate generally less than 15%) (Forner et al., 2012) . The strong carcinogenic "field effect" in the cirrhotic liver clearly indicates that cirrhosis is a rational target to explore cancer chemoprevention biomarkers and therapies . However, the diversity of etiological agents, namely hepatitis C virus (HCV), hepatitis B virus (HBV) , alcohol abuse, and non-alcoholic fatty liver diseases (NAFLD)/non-alcoholic steatohepatitis (NASH), has precluded identification of broadly applicable cancer risk biomarkers that could potentially salvage the HCC surveillance program that has collapsed due to the vast size of the cirrhotic population (Davila et al., 2010) .
To address this unmet need and establish the first step of our "reverse-engineering" approach, we have identified and validated a 186-gene HCC risk-predictive signature in liver tissues (HCC risk gene signature), which was stable across multiple sampling sites in the liver and not affected by presence or absence of HCC tumor in the liver, in multiple independent patient cohorts enrolled from Asia, Europe, and the U.S., mainly affected by HCV infection and clinically followed for up to 23 years (Hoshida et al., 2008; Hoshida et al., 2013; King et al., 2015) . The gene signature successfully monitored the HCC chemopreventive effect of an FDA-approved small molecule epidermal growth factor (EGF) pathway inhibitor, erlotinib, in multiple rodent models of cirrhosis-driven HCC , which led to initiation of a proof-of-concept, biomarker-guided cancer chemoprevention clinical trial (ClinicalTrials.gov, NCT02273362). However, it is still undetermined whether the gene signature is universally applicable beyond HCV. Moreover, adverse effects of erlotinib limit its wide-spread use as a preventive medicine and therefore indicate the necessity to further identify better HCC chemoprevention targets. Here our goals were to establish the clinical HCC risk gene signature assay in all major HCC etiologies, elucidate global molecular regulatory networks in cirrhotic liver for HCC chemoprevention target discovery, and to demonstrate the feasibility of fast-track, simultaneous identification of cancer chemoprevention targets, drugs, and biomarkers ready for clinical assessment.
RESULTS

Pan-etiology HCC risk gene signature
In our previous studies, the HCC risk gene signature has been validated for its association with future cancer risk in fibrotic/cirrhotic patients mainly affected by chronic HCV infection ( Figure S1A , Cohort 1-4, n=668 in total) (Hoshida et al., 2008; Hoshida et al., 2013; King et al., 2015) . Reanalysis of publicly available datasets of patient series affected with HBV, alcohol abuse, and NASH showed significant association of the signature with clinical outcome or disease severity ( Figure S1B ). To verify the findings with a clinically applicable assay, we implemented a reduced version of the 186-gene HCC risk gene signature bioinformatically defined in our recent study (32-gene signature) (King et al., 2015) in an FDA-approved digital transcript counting technology (Elements assay, NanoString). Technical validation demonstrated a high reproducibility of the gene expression measurements with the assay ( Figure S1C ). The assay was tested in liver tissues from an independent cohort of surgically-treated, early-stage HCC patients (n=263, Cohort 5) related to either of HCV, HBV, alcohol, or NAFLD/NASH, and followed for up to 23 years (Table S1 ). Complete removal of the tumors was histologically and radiologically confirmed. Recurrence hazard plot showed that the recurrences are dominantly de novo recurrence rather than dissemination/metastasis of the primary tumors (see Figure S1D for details). With the gene signature-based prediction, 57 (22%), 148 (56%), and 58 (22%) patients were classified into high-, intermediate-, and low-risk groups, respectively ( Figure  1A ). Concordant prognostic prediction between permutation of genome-wide and only signature genes was observed in our previously generated genome-wide transcriptome profiles (Cohort 1, Figure S1E ). These risk groups were strikingly associated with de novo HCC recurrence ( Figure 1B) . Interestingly, the HCC risk gene signature quantitatively depicted the relative risk status of the liver according to etiology ( Figure 1A ). HBV-infected liver showed relatively lower risk status (p<0.001, Kolmogorov-Smirnov test) consistent with the clinical observation that HBV-related HCC is associated with less frequent postsurgical/ablative HCC development compared to HCV in both Western and Eastern patient cohorts (Franssen et al., 2014; Minami et al., 2015) . In contrast, NAFLD/NASH-affected livers accumulated on the higher risk side (p<0.001) despite the lowest frequency of established cirrhosis (23% in NAFLD, 21% in NASH). This echoes the recently recognized epidemiological evidence that NAFLD/NASH-related HCC often develops in the liver with earlier-stage fibrosis (Kawada et al., 2009) . Annual HCC incidence rate was nearly 4-fold higher in patients with high-risk prediction (41%/year) compared to low-risk prediction (11%/year) ( Table S1 ). The prognostic association remained significant for each etiology subgroup in multivariable Cox regression adjusted for known clinical prognostic variables ( Figure 1C ). Of note, the prognostic association was significant in the subgroup of NASH patients (p=0.03), but not in NAFLD patients (p=0.14) in multivariable Cox regression. This indicates that presence of inflammation, i.e., steatohepatitis, is critical for the gene signature to be prognostic, and there is a need for complementary prognostic indicators for NAFLD patients who lack hepatic inflammation. Collectively, the results support panetiology prognostic capability of the gene signature assay in patients affected with HCV, HBV, alcohol, or NASH.
HCC risk prediction after pharmacological HCV eradication
The recent emergence of directly acting-antiviral regimens (DAAs) for HCV has enabled high rates of complete viral eradication, i.e., sustained virologic response (SVR) . Although SVR was epidemiologically associated with reduced HCC incidence in patients with advanced fibrosis, the risk of HCC is not eliminated and persists beyond a decade even after achieving an SVR (Morgan et al., 2013; van der Meer et al., 2012) . Therefore, HCC risk prediction after SVR is urgently needed. Among the validation cohort (Cohort 5) patients infected with HCV (n=67), 4 patients achieved SVR prior to HCC development and showed relatively lower risk pattern of the HCC risk signature ( Figure 1D ), suggesting that SVR could modulate the molecular cancer risk status of the liver measured by the signature. Therefore, we next asked whether a change in the HCC risk gene signature expression after SVR is associated with future HCC risk by analyzing paired liver biopsy specimens obtained before and after antiviral therapy from 34 patients who never had HCC (median time from the second biopsy to the last observation: 6.0 years, IQR: 5.1-7.8 years). The magnitude of gene signature reversal, i.e., suppression of the HCC high-risk genes and restoration of the HCC low-risk genes in the signature, was the largest in 13 SVR subjects free of HCC at the end of follow-up ( Figure 1E ). Of note, 14 SVR patients who subsequently developed HCC showed less gene signature reversal even when compared to non-responders (NR) who did not develop HCC. Despite unsuccessful anti-HCV treatment, 4 out of the 5 HCC-free NR patients achieved resolution of clinically active hepatitis, i.e., normalization of elevated hepatic transaminases so-called biochemical response, which was associated with reduced HCC risk , consistent with the larger gene signature reversal. In contrast, the SVR patients who had HCC similarly achieved normalization of transaminases, suggesting that the persisting HCC risk post SVR is not due to continued hepatic inflammation, but due to other unknown factors, which can be quantified by the HCC risk gene signature. These results collectively suggest that the gene signature assessment could be a promising quantitative HCC risk predictor after HCV eradication.
Global transcriptomic landscape of fibrotic human livers
We next explored pan-etiology targets of HCC chemoprevention by determining the systems-level dysregulation of the fibrotic/cirrhotic liver transcriptome. Regulatory gene network modeling was performed by synthesizing genome-wide transcriptome profiles of clinical fibrotic/cirrhotic liver tissues generated in our previous studies (Hoshida et al., 2008; Hoshida et al., 2013 ) (Cohort 1-3, n=523 in total, Figures 2A and S2A ). Gene co-expression meta-analysis followed by Planar Filtered Network Analysis (PFNA) identified 31 tightly co-regulated gene modules, forming 2 major groups connected by 3 central hub modules (no.2, 3, and 8) ( Figure 2B ). Molecular pathways/functions, which have been implicated in the pathogenesis of liver inflammation, fibrogenesis, and carcinogenesis, were identified in the modules (Table S2 ). Gene module no.14, which was enriched with growth signaling pathways, contained the EGF pathway, which we identified as an HCC chemoprevention target in our previous study , which was directly connected to one of the central hub modules, suggesting a close regulatory relationship between them. Interestingly, the HCC risk gene signature was associated with known cancerous conditions in multiple organs such as colon mucosa affected with ulcerative colitis (but not Crohn's disease, consistent with clinical observation), actinic keratosis (a precursor lesion of non-melanoma squamous cell carcinoma caused by long-term sun exposure), and diabetes (Calle et al., 2003; Itzkowitz et al., 2005) (Tables S3 and 4 and Figures S2B-E). Transforming growth factor-β (TGF-β), which was enriched in the stress response/RhoA module (no. 3), was inferred as a common top upstream regulator of the cross-organ carcinogenic gene dysregulations together with other cytokine-encoding genes, e.g., TNF and IL6 (Table S5) , which indeed induced the HCC risk gene signature in lung epithelial cell line and organotypic ex vivo culture of non-diseased human liver tissues (Figures S2F and G) . Indeed, RHOA is a transcriptional target of the TGF-β pathway (see "Transcriptional targets of TGF-β pathway activation" in Supplemental Experimental Procedures).
In human cirrhosis, the gene modules of stress response (no.2 and 3), extracellular matrix (ECM) (no.19), and interferon (no.24 and 28) were strongly induced, whereas the hepatocyte modules (no.9, 22, 23, and 26) were suppressed ( Figure 3 , Table S6 ). Several chemically, physiologically, or genetically-induced rodent models of liver fibrosis and/or HCC recapitulate the dysregulation of the HCC risk gene signature and the cirrhosis gene modules to varying degrees, underscoring their utility in testing chemoprevention strategies targeting specific gene module dysregulation. The repeated, low-dose diethylnitrosamine (DEN)-induced cirrhosis-driven HCC rat (low-dose DEN rat) is one of the models that showed the most striking induction of the HCC risk gene signature and global similarity in dysregulation of the cirrhosis gene modules. In this model, transcriptome profiles of hepatocyte and hepatic stellate cell fractions showed that the pattern of gene module dysregulation was generally comparable, suggesting the presence of intensive cross-talks between the cell types, while induction of the growth signaling module and stress response/ECM modules was relatively stronger in hepatocytes and hepatic stellate cells, respectively. Therapeutic modulation, i.e., reversal of the dysregulated HCC risk gene signature and the cirrhosis gene modules, could also be monitored for anti-fibrotic and/or HCC chemopreventive treatments, including a small molecule EGF receptor inhibitor erlotinib , epigallocatechin gallate (EGCG, a green tea polyphenol), ghrelin (a "hunger" hormone), and vitamin D, depicting the utility of monitoring the cirrhosis gene modules in assessing clinical relevance of experimental HCC chemoprevention therapies.
Computational identification of LPA pathway as a functional key regulator of cirrhosisdriven carcinogenesis
In human cirrhosis, the central hub module, no.8, which is located at the center of the global cirrhosis gene networks, was the only module uniquely activated in association with increased risk of future de novo HCC recurrence, but not with presence of cirrhosis ( Figure  3 , the second column compared to the first column from the left), which suggested its specificity to carcinogenesis and reasoned us to explore the drivers of carcinogenesis in the module. In fact, computationally inferred hub key driver genes in the module and tightlyconnected neighboring modules, no.2 and 3, were enriched with genes implicated in carcinogenesis: HINT1 has been described as a tumor suppressor gene in HCC (Calvisi et al., 2009; Zhang et al., 2009 ), UBE2K encodes an E2 ubiquitin ligase involved in p53 degradation (Saville et al., 2004) , YY1 encodes an oncogenic transcription factor in HCC that is also known to suppress p53 pathway (Gordon et al., 2006) , and ATP5J2, which encodes a protein known to physically interact with c-Myc ( Figure 4A ) (Agrawal et al., 2010) . Indeed, HIP2 and YY1 expression was negatively correlated with p53 activation status, and ATP5J2 expression was positively correlated with induction of Myc pathway target genes in the 3 human fibrosis/cirrhosis cohorts (Cohort 1-3, Figures S3A-C) . RHOA was another hub gene of the module no.3 together with its known target MRCL3, encoding myosin regulatory light chain, as well as fibrosis-related genes such as CCL5 (Berres et al., 2010) (Figure 4A ).
To identify functional regulators of the genes in module no.8, we systematically surveyed enrichment of experimental genetic perturbation transcriptome signatures defined by shRNA library-based knockdown of 5,272 genes in an unbiased manner (the transcriptome signatures were generated using the dataset from NIH Library of Integrated Cellular Signatures [LINCS] project, www.lincsproject.org) (see Supplemental Experimental Procedures). Top enriched upstream regulator genes were AKT1, SLC35A1, DDX42, LPAR1, and ILK ( Figure 4B ). Indeed, Akt/mechanistic target of rapamycin (mTOR)/ phosphoinositide 3-kinase (PI3K) pathway inhibitors, everolimus and sirolimus, are currently being tested in clinical trials for prevention of post-liver transplantation HCC recurrence (Burra and Rodriguez-Castro, 2015) . Among the rest, LPAR1 was the only one encodes a protein selectively targetable with compounds currently under clinical development. Lysophosphatidic acid receptors (LPARs) form a family of G protein-coupled receptors, and LPAR1 has been shown to promote fibrosis in multiple organs by upregulating pro-fibrogenic mediators, including connective tissue growth factor (CTGF), known to be elevated in activated hepatic stellate cells (Huang and Brigstock, 2012; Pradere et al., 2007; Sakai et al., 2013; Tager et al., 2008) . In liver, expression of autotaxin (ATX), which converts lysophosphatidylcholine (LPC) into LPA (ligand for LPAR), is elevated in serum of HCV-infected patients, especially in those with HCC and/or severe fibrosis (Cooper et al., 2007; Nakagawa et al., 2011; Watanabe et al., 2007) . In consistent, AKAP13, an HCC risk signature member gene, encodes a guanine exchange factor that relays the signal to downstream of the RhoA signaling pathway, further supporting the role of LPA pathway as a functional driver of HCC development.
It is known that RhoA, Ras/mitogen-activated protein kinase kinase (MAPK)/extracellular signal-regulated kinase (ERK)/MAPK/ERK kinase (MEK), Akt/PI3K, and phospholipase C (PLC) pathways are downstream effectors of the LPA pathway (Kihara et al., 2015) . In Cohort 5, expression of NCAPH (RhoA pathway target), PRKG2 (K-Ras pathway target), SERPINB2 (H-Ras pathway target), and GPX2 (MEK pathway target) gradually increased according to the HCC risk signature-based stratification ( Figure S3D ). Transcriptome-based unbiased in silico screening of 20,413 chemical perturbation in the LINCS database using the HCC risk gene signature as a query yielded selective inhibitors of Rho kinase, Akt/PI3K, and MAPK/ERK/MEK pathways, further supporting the involvement of the LPA downstream pathways (Table S7) . These results collectively support that the LPA pathway activation is robustly observed in human and rodent cirrhotic livers at risk of HCC development, representing an HCC chemoprevention target.
In vivo pharmacological LPA pathway inhibition suppressed HCC development, and reversed HCC risk gene signature
We next examined HCC chemopreventive effects of LPA pathway inhibition by using selective ATX (AM063) and LPAR1 (AM095) inhibitors ( Figure S4A ). To examine involvement of the RhoA pathway, two Rho kinase (ROCK) inhibitors, Fasudil and Y-27632, were tested in a fibrogenic human hepatic stellate cell line, TWNT-4, along with AM095. All of the three compounds similarly suppressed LPA-induced phosphorylation of myosin regulatory light chain (pMRLC), indicator of RhoA pathway activation ( Figure S4B ). Suppression of pERK (downstream of another LPA target, MEK/Ras pathways), was unique to AM095, consistent with the established specificity of the compound to the LPA pathway (Stein et al., 2015; Swaney et al., 2011) . In contrast, pAkt was suppressed by LPA pathway activation and restored by AM095, suggesting that the Akt and LPA pathways are in negative feedback with each other in the liver, and LPA signaling represents an HCC chemoprevention target distinct from the Akt pathway. TGF-β is one of the major profibrogenic factors in the liver, which has been extensively studied as a potential therapeutic target and is known as an upstream regulator of CTGF . TGF-β neutralizing antibody had no effect on the LPA downstream pathways. LPA-induced CTGF expression was suppressed by AM095 and, to a lesser extent, Y-27632 whereas TGF-β neutralizing antibody had no effect ( Figure S4C ). shRNA-based knockdown of LPAR1 and RHOA expression resulted in similar suppression of LPA-induced CTGF expression ( Figures S4D and E ).
In the low-dose DEN rat model of cirrhosis-driven HCC, which manifests global transcriptomic and histological similarity to human (Figures 3 and S4F) , plasma ATX activity and hepatic Lpar1 expression gradually increased as cirrhosis developed ( Figures 5A-5C ). Hepatic Ctgf expression similarly increased mainly in hepatic stellate cell fraction ( Figure S4G ). Atx expression was higher in the hepatocyte fraction, whereas Lpar1 were expressed predominantly in the stellate cell fraction, collectively suggesting that cross-talk between the cell types results in the LPA pathway activation in the liver tissue ( Figure S4H ). Ten-week administration of AM063 or AM095 significantly reduced hepatic expression of Ctgf, collagen 1 (Col1a1), and α-smooth muscle actin (α-SMA, Acta2), the major extracellular matrix proteins secreted from activated hepatic stellate cells ( Figure S4I ). Histological liver fibrosis was attenuated and, as bioinformatically predicted, HCC nodules were significantly reduced ( Figures 5C-F) . Correspondingly, transcriptome profiling of the rat livers by RNA-Seq demonstrated reversal of the HCC risk gene signature and dysregulation of human cirrhosis gene modules along with the LPA downstream pathways and the hepatic stellate cell gene signature (Zhang et al., 2016) ( Figure 5G ). The driver genes of the hub cirrhosis gene modules (no.2, 3, 8) and EGF pathway targets were suppressed by the compounds, whereas modulation of TGF-β pathway targets was moderate ( Figure S4J ). In summary, the pharmacological LPA pathway inhibition elicited HCC chemopreventive effect via suppression of RhoA and ERK pathways, but not Akt and TGF-β pathways. Neither of the compounds showed evidence of hepatotoxicity, while decreased serum levels of bilirubin was observed consistent with the histological improvement of liver fibrosis ( Figure S4K ).
HCC risk gene signature reversal by LPA pathway inhibition in organotypic ex vivo culture of human fibrotic liver tissues
Finally, we sought to determine whether the reversal of the HCC risk gene signature, which was accompanied with the in vivo HCC chemopreventive effect by LPA pathway inhibition, can be monitored in human liver tissues. We first confirmed that induction of the HCC risk gene signature as well as our hepatic stellate cell signature (Zhang et al., 2016) was preserved in organotypic ex vivo culture of carbon tetrachloride-induced fibrotic mouse liver tissue up to 48 hr, even without continued chemical treatment, suggesting that fibrotic tissue microenvironment is sufficient for perpetuation of the gene signature induction in the culture ( Figure S5A ). Subsequently, 13 clinical human liver tissues (male: 7, female: 6; HBV: 5, HCV: 3, NASH: 1, and cryptogenic: 4) were similarly cultured ex vivo with AM095 for 48 hr. HCC risk gene signature prediction was performed using the tissues before culture (Figures 6 and S5B ). With the drug treatment, varying degrees of HCC high-risk gene suppression, HCC low-risk gene restoration, and/or combinatorial reversal were observed ( Figure 6 ). The presence of HCC high-risk gene signature before the drug treatment (p=0.008, Wilcoxon rank-sum test) as well as less liver fibrosis (p=0.01, Pearson correlation test) were associated with greater gene signature reversal, suggesting that these factors may predict gene signature response to AM095 in actual clinical setting. At gene and molecular pathway levels, suppression of growth signaling (EGF, IGFBP6, EPHA4), extracellular matrix protein-encoding genes (COL6A3, COL16A1, LOXL2), cell adhesion and fibrogenic cytokines (LPP, PODXL, CTNND2, CXCR4, CCL21) and oxidative stress (GPX2, NOS2A) as well as restored expression of plasma protein-encoding genes (PLG, C8B, C5, TTR) were the main features observed in the gene signature responders. The hepatic stellate cell signature was suppressed in patients with reversed HCC risk gene signature (p=0.045, Wilcoxon rank-sum test). These results suggest that the HCC risk gene signature or serum LPA level or proteomic surrogates of the tissue-based gene signature (Cooper et al., 2007; Muir et al., 2013; Nakagawa et al., 2011; Watanabe et al., 2007) could serve as a companion biomarker for pharmacological LPA pathway inhibition to identify potential responders and monitor the therapeutic effect in future HCC chemoprevention trials. In fact, when enrollment in adjuvant chemoprevention trials following curative treatment is limited to subjects with the HCC high-risk gene signature, the estimated sample size is comparable to those required in cancer therapeutic trials, i.e., up to a few hundred ( Figure S5C ).
DISCUSSION
Cancer chemoprevention is a major unmet medical need with numerous challenges during both preclinical and clinical development . It is typically not feasible to experimentally model the entire physiological process of cancer development in order to evaluate the effect of cancer-preventive intervention. Cancer chemoprevention clinical trials enrolling cancer-free asymptomatic individuals require larger sample sizes and longer follow-up time compared to advanced-stage cancer therapeutic trials due to a smaller event rate (Lippman et al., 2009) . Even when clinical risk factors are known, thousands of individuals are generally required to be enrolled and followed for longer than 5 years to detect cancer preventive effect (Cuzick et al., 2014) . Therefore, molecular biomarkers of cancer risk that further enrich high-risk population will lower the bar to conducting cancer chemoprevention trials. Our HCC risk signature, which was validated in all major HCC etiologies including post HCV cure, will have a wide range of applicability as a pan-etiology companion biomarker for HCC chemoprevention clinical trials.
The cirrhosis gene regulatory modules provide a systems-level landscape of molecular dysregulation common to a wide range of liver disease etiologies. Projection of the global transcriptome onto the cirrhosis gene module map will enable rapid and straightforward identification of experimental models that best resemble human cirrhosis according to the molecular targets of interest. Our study demonstrates that the LPA pathway is one of the central regulators of human cirrhosis pathogenesis and a promising target for HCC chemoprevention, one made more feasible by the existence of compounds in clinical development for non-cancer patients with negligible toxicity (Kihara et al., 2015) . Although TGF-β pathway has been studied as an anti-fibrosis target, clinical inhibition of the pathway has been deemed challenging due to systemic toxicities and may not be justified as a preventive intervention for asymptomatic and still cancer-free individuals Mehal and Schuppan, 2015) . Our results suggest that LPA pathway inhibition is an alternative way to antagonize downstream targets to achieve HCC chemoprevention, while circumventing the toxicities of directly targeting TGF-β pathway.
Collectively, our study demonstrates that transcriptome analysis of cancer-prone, chronically-diseased organs with long-term clinical observation is a viable and effective approach to uncover cancer chemoprevention biomarkers and targets. This approach will be widely applicable to other cancer types driven by chronic organ inflammation and/or fibrosis, as a paradigm, reverse-engineering precision cancer prevention.
EXPERIMENTAL PROCEDURES
More detailed procedures are described in the Supplemental Information.
Patient cohorts
Prognostic association of the HCC risk gene signature was validated in an independent cohort of 263 consecutive patients with curatively resected HCC at Toranomon Hospital or Kumamoto University Hospital between 1988 and 2012. Paired liver biopsy tissues were obtained before and after anti-HCV therapy for patients with chronic hepatitis C at Toranomon Hospital and Kaohsiung Medical University Hospital between 2004 and 2009. The study was approved by institutional review board (IRB) at Mount Sinai Hospital, Toranomon Hospital, Kumamoto University Hospital, and Kaohsiung Medical University Hospital for anonymous analysis of de-identified archived waste FFPE tissues from previous routine clinical care without written informed consent.
HCC risk gene signature profiling
Archived FFPE liver tissues were analyzed by the 32-gene HCC risk signature (King et al., 2015) implemented in nCounter Elements assay (NanoString). Prognostic prediction was performed as previously described (King et al., 2015) . Prognostic association of the gene signature was evaluated by log-rank test and multivariable Cox regression modeling adjusted for clinically well-established prognostic variables. All analyses were performed using R statistical language (www.r-project.org) and GenePattern (www.broadinstitute.org/ genepattern).
Human cirrhosis regulatory gene modules
Functionally co-regulated gene modules in human fibrotic/cirrhotic liver tissues were determined in genome-wide transcriptome profiles of 3 independent patient cohorts (n=523) using Fisher's inverse chi-square statistic (Fisher, 1932) and Planar Filtered Network Analysis (PFNA) algorithm (Song and Zhang, 2015) . Induction or suppression of the gene modules as was assessed in a panel of in vitro and in vivo experimental models of liver diseases and HCC (Table S6 ) using Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) .
In vitro and in vivo pharmacological LPA pathway inhibition
The ATX inhibitor AM063 and the LPAR1 antagonist AM095 were provided by Amira Pharmaceuticals and Bristol Myers Squibb, and tested in human hepatic stellate cell line, TWNT-4, and male Wistar rats (Charles River) treated with low-dose (50 mg/kg) weekly injection of diethylnitrosamine (DEN) as previously described following Guide for the Care and Use of Laboratory Animals (National Academy of Sciences) and the institutional guidelines, and the protocol was approved by Massachusetts General Hospital Subcommittee on Research Animal Care. Tumor nodules were counted in serial liver sections, and primary hepatocytes and hepatic stellate cells were isolated from fresh liver tissue using an established protocol . Gene expression was measured by real-time PCR. Total/phosphorylated MRLC, collagen 1, and α-SMA protein levels were determined by western blotting as previously described . Liver fibrosis stained by sirius red was quantified using Image J software (imagej.nih.gov/ij) as collagen proportionate area. Intergroup difference was evaluated by t-test with Bonferroni correction as needed.
Organotypic ex vivo culture of experimental and clinical liver tissues
Fresh liver tissues from carbon tetrachloride (CCl 4 )-treated strain A/J male mice (Jackson Laboratory) and de-identified surgically resected human liver tissues (obtained via Mount Sinai Biorepository with IRB-approved written informed consent) were sliced into 300 µm-thick tissue sections, and the human livers were cultured with the LPA pathway inhibitor AM095 (3 µM) or DMSO for 48 hr. Expression of HCC risk gene signature was determined before and after the culture using the Elements assay, and modulation of the signature by AM095 was determined by GSEA.
Transcriptome profiling of rodent livers
Transcriptome profiling of rodent liver was performed by RNA-Seq, RatRef-12 beadarray, or MouseRef-8 beadarray (Illumina) as previously described . Rodent genes were converted into orthologous human genes using a mapping table obtained from NCBI HomoloGene database (build 68). Induction or suppression of target genes of relevant cellular signaling pathways was assessed by GSEA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
SIGNIFICANCE
Chronically inflamed and/or fibrotic organ is a clinically well-known "soil" that develops cancer, although it has been challenging to identify clinically relevant cancer chemoprevention targets in the organ and therapies due to complex molecular dysregulation involving multiple cell types, lengthy process of carcinogenesis, and the lack of cancer risk biomarkers to enable their clinical testing. Here we show a strategy to systematically utilize diseased organ transcriptome to simultaneously identify clinically relevant cancer chemoprevention biomarkers, targets, and therapies by integrating clinical cancer risk based on several decades of clinical observation. This approach is applicable to other cancer types arisen from chronically diseased organs, and will facilitate development of molecular targeted cancer chemoprevention therapies.
HIGHLIGHTS
•
Clinically applicable pan-etiology HCC risk biomarker was established.
• Global transcriptome map of cirrhosis identified HCC chemoprevention targets.
• Global transcriptome map of cirrhosis identified clinically-relevant animal models.
• LPA pathway inhibitors were verified as HCC chemopreventive and antifibrotic drugs. Figure S1 and Table S1 . Activation status of each cirrhosis gene module was assessed by Gene Set Enrichment Analysis, and visualized as gene set enrichment index (GSEI) calculated from gene set enrichment p value based on iterative random gene permutations (1,000 times for each module in each condition). Orange and green colors in heatmap indicate statistical significance of induction and suppression of each gene module, respectively, in association with each phenotype or intervention in each model. GSEI of +3 indicates induction (orange) at enrichment p=0.001, GSEI of −3 indicates suppression (green) at enrichment p=0.001, and GSEI of 0 indicates no modulation (white) at enrichment p=1.0. In "Cirrhosis (human)" column, genes in the transcriptome dataset were rank-ordered according to differential expression between cirrhotic and healthy livers to compute GSEI. In "HCC high risk (human)" column, genes were rank-ordered according to association with time to HCC development measured by Cox score (Hoshida et al., 2008) Figure S3 and Table S7 . HCC risk gene signature prediction was determined using tissues before the treatment. Modulation of HCC risk gene signature and hepatic stellate cell signature by AM095 is presented as gene set enrichment index (GSEI). Modulation of the signature member genes is presented as log2-fold change compared to respective DMSO-treated controls. Orange and green colors in the upper heatmap indicate induction and suppression of gene signature by GSEI, respectively. GSEI of +3 indicates induction (orange) at enrichment p=0.001, GSEI of −3 indicates suppression (green) at enrichment p=0.001, and GSEI of 0 indicates no Nakagawa et al. Page 28 Cancer Cell. Author manuscript; available in PMC 2017 December 12.
